Results 11 to 20 of about 25,820 (298)
Targeting hyperphosphatemia: truth or dare [PDF]
Kidney International, 2010 To the Editor: We are pleased that Isakova et al.1 have generated the momentum for long-awaited randomized trials on phosphorus management in patients with chronic kidney disease. We fully agree that these are long overdue. Treatment of millions of patients worldwide, following the Kidney Disease Outcome Quality Initiative guidelines,2 is based on ...
Björn Meijers, Pieter Evenepoel
openaire +3 more sources
Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease [PDF]
Scientific Reports, 2017 Medial arterial calcification (MAC) and renal osteodystrophy are complications of mineral bone disease (MBD) associated with chronic kidney disease (CKD). Our aim was to develop a novel mouse model to investigate the clinical course of CKD-MBD.
T. Tani +3 more
semanticscholar +2 more sources
The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease [PDF]
Терапевтический архив, 2016 Aim. To study whether the excessive production of serum fibroblast growth factor 23 (FGF-23) may be reduced with phosphate-binding agents to treat hyperphosphatemia in patients with Stage VD chronic kidney disease (CKD). Subjects and methods.
N A Mukhin +4 more
doaj +2 more sources
Journal of the American Medical Association (JAMA), 2021 Importance Among patients with hyperphosphatemia undergoing dialysis, it is unclear whether non-calcium-based phosphate binders are more effective than calcium-based binders for reducing cardiovascular events.
H. Ogata +5 more
semanticscholar +1 more source
Medicina, 2023 Hyperphosphatemia is a secondary disorder of chronic kidney disease that causes vascular calcifications and bone-mineral disorders. As per the US Centers for Disease Control and Prevention, renal damage requires first-priority medical attention for ...
Ajeeta Anand, Hideki Aoyagi
doaj +1 more source
Phosphate intake, hyperphosphatemia, and kidney function
Pflügers Archiv: European Journal of Physiology, 2022 Phosphate is essential in living organisms and its blood levels are regulated by a complex network involving the kidneys, intestine, parathyroid glands, and the skeleton.
I. Rubio-Aliaga, R. Krapf
semanticscholar +1 more source
Journal of the American Society of Nephrology, 2021 Significance Statement In patients receiving maintenance dialysis, strategies for managing hyperphosphatemia are only moderately effective. In this 4-week randomized trial involving 236 patients experiencing hyperphosphatemia despite phosphate binder use,
P. Pergola +3 more
semanticscholar +1 more source
Spurious Hyperphosphatemia in a Patient with Multiple Myeloma: A Case Report
Journal of Health Science and Medical Research (JHSMR), 2021 Spurious hyperphosphatemia has been reported periodically in multiple myeloma (MM) patients with paraproteinemia. It is important for clinicians to recognize this phenomenon in order to avoid misdiagnosis and unnecessary treatment for true ...
Thakorn Pruktanakul +1 more
doaj +1 more source
Frontiers in Nephrology, 2022 Objective This study was intended to explore the relationship between level of serum phosphate and prognosis in septic patients. Methods Data were obtained from the public database, which were divided into 2 subgroups according to whether they were ...
Zheng-xia Liu +4 more
semanticscholar +1 more source
Majalah Kedokteran Bandung, 2022 Increased chronic kidney disease (CKD) mortality rate is significantly associated with increased blood phosphate levels. Hyperphosphatemia control is one of the main focuses in the management of hemodialysis (HD) patients.
Made Dyah Vismita Indramila Duarsa +3 more
doaj +1 more source